Hagemann AR, Hagemann IS, Mutch DG, Devor EJ, Malmrose PK, Zhang Y, Morrison AM, Thiel KW, Leslie KK. Enhancing Progestin Therapy with a Glucagon-Like Peptide 1 Agonist for the Conservative Management of Endometrial Cancer. Cancers (Basel). 2025 Feb 10;17(4):598. doi: 10.3390/cancers17040598. PMID: 40002193; PMCID: PMC11853405. https://www.mdpi.com/2072-6694/17/4/598

Colling KE, Symons EL, Buroni L, Sumanasiri HK, Andrew-Udoh J, Witt E, Losh HA, Morrison AM, Leslie KK, Dunnill CJ, de Bono JS, Thiel KW. Multiplexed Live-Cell Imaging for Drug Responses in Patient-Derived Organoid Models of Cancer. J Vis Exp. 2024 Jan 5;(203). doi: 10.3791/66072. PMID: 38251777.

Ruiz-Ciancio D, Veeramani S, Singh R, Embree E, Ortman C, Thiel KW, Thiel WH. AptamerRunner: An accessible aptamer structure prediction and clustering algorithm for visualization of selected aptamers. Mol Ther Nucleic Acids. 2024 Oct 9;35(4):102358. doi: 10.1016/j.omtn.2024.102358. PMID: 39507401; PMCID: PMC11539416.

Colling KE, Symons EL, Buroni L, Sumanisiri HK, Andrew-Udoh J, Witt E, Losh HA, Morrison AM, Leslie KK, Dunnill CJ, De Bono JS, Thiel KW. Multiplexed live-cell imaging for drug responses in patient-derived organoid models of cancer. bioRxiv [Preprint]. 2023 Nov 17:2023.11.15.567243. doi: 10.1101/2023.11.15.567243. PMID: 38014133; PMCID: PMC10680710. https://www.biorxiv.org/content/10.1101/2023.11.15.567243v1

Thiel KW, Newtson AM, Devor EJ, Zhang Y, Malmrose PK, Bi J, Losh HA, Davies S, Smith LE, Padilla J, Leiva SM, Grueter CE, Breheny P, Hagan CR, Pufall MA, Gertz J, Guo Y, Leslie KK.Global expression analysis of endometrial cancer cells in response to progesterone identifies new therapeutic targets. J Steroid Biochem Mol Biol. 2023 Nov;234:106399. doi: 10.1016/j.jsbmb.2023.106399. Epub 2023 Sep 15. PMID: 37716459; PMCID: PMC11171468. https://www.sciencedirect.com/science/article/pii/S0960076023001541?via%3Dihub

Rush CM, Blanchard Z, Polaski JT, Osborne KS, Osby K, Vahrenkamp JM, Yang CH, Lum DH, Hagan CR, Leslie KK, Pufall MA, Thiel KW, Gertz J. Characterization of HCI-EC-23 a novel estrogen- and progesterone-responsive endometrial cancer cell line. Sci Rep. 2022 Nov 17;12(1):19731. doi: 10.1038/s41598-022-24211-8. PMID: 36396974; PMCID: PMC9672046. https://www.nature.com/articles/s41598-022-24211-8

Leslie KK, Thiel K. Leslie KK, Thiel K. Reply to E. Guerra et al. J Clin Oncol. 2023 Jan 1;41(1):147. doi: 10.1200/JCO.22.01656. Epub 2022 Sep 16. PMID: 36112967. https://ascopubs.org/doi/10.1200/JCO.22.01656?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

Thiel KW, Devor EJ, Filiaci VL, Mutch D, Moxley K, Alvarez Secord A, Tewari KS, McDonald ME, Mathews C, Cosgrove C, Dewdney S, Aghajanian C, Samuelson MI, Lankes HA, Soslow RA, Leslie KK. TP53 Sequencing and p53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study. J Clin Oncol. 2022 Oct 1;40(28):3289-3300. doi: 10.1200/JCO.21.02506. Epub 2022 Jun 3. PMID: 35658479; PMCID: PMC9553389.

Bi J, Zhang Y, Malmrose PK, Losh HA, Newtson AM, Devor EJ, Thiel KW, Leslie KK. Blocking autophagy overcomes resistance to dual histone deacetylase and proteasome inhibition in gynecologic cancer. Cell Death Dis. 2022 Jan 17;13(1):59. doi: 10.1038/s41419-022-04508-2. PMID: 35039480. https://www.nature.com/articles/s41419-022-04508-2

Bi J, Dixit G, Zhang Y, Devor EJ, Losh HA, Newtson AM, Coleman KL, Santillan DA, Maretzky T, Thiel KW, Leslie KK, Advantages of Tyrosine Kinase Anti-Angiogenic Cediranib over Bevacizumab: Cell Cycle Abrogation and Synergy with Chemotherapy. Pharmaceuticals (Basel). 2021 Jul 16;14(7):682. PMID: 34358108; PMCID: PMC8308742. https://doi.org/10.3390/ph14070682.